Table 4. Change in Cardiac Biomarkers From Baseline to 12 Weeks by Treatment Group.
| Parameters | Sacubitril-Valsartan | Enalapril | Ratio of Sacubitril-Valsartan vs Enalapril, Geometric Mean (95% CI) | P Value Between Groups | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | Baseline, Geometric Mean (95% CI) | Week 12, Geometric Mean (95% CI) | Ratio of Geometric Means, 12 wk/Baseline (95% CI) | No. | Baseline, Geometric Mean (95% CI) | Week 12, Geometric Mean (95% CI) | Ratio of Geometric Means, 12 wk/Baseline (95% CI) | |||
| Secondary End Points | ||||||||||
| NT-proBNP, pg/mL | 211 | 574 (482-682) | 363 (307-430) | 0.63 (0.58-0.69) | 215 | 569 (474-683) | 541 (449-651) | 0.95 (0.87-1.0) | 0.67 (0.59-0.76) | <.001 |
| Exploratory End Points | ||||||||||
| Soluble ST2, ng/mLa | 206 | 27.6 (26.0-29.2) | 26.1 (24.7-27.6) | 0.95 (0.92-0.98) | 211 | 25.8 (24.4-27.2) | 26.3 (24.8-27.9) | 1.01 (0.98-1.05) | 0.94 (0.89-0.98) | .006 |
| hs-TnT, ng/L | 204 | 0.017 (0.016-0.019) | 0.015 (0.014-0.017) | 0.87 (0.84-0.91) | 208 | 0.018 (0.017-0.019) | 0.019 (0.018-0.021) | 1.05 (1.0-1.09) | 0.83 (0.78-0.88) | <.001 |
| Urinary cGMP/creatinine, μmol/mol | 205 | 67.0 (62.0-72.4) | 89.4 (83.1-96.2) | 1.34 (1.27-1.41) | 205 | 60.6 (56.0-65.5) | 58.2 (53.9-63.0) | 0.96 (0.91-1.02) | 1.44 (1.33-1.55) | <.001 |
Abbreviations: cGMP, cyclic guanosine monophosphate; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
a
ST2 is a member of the interleukin 1 receptor family and is expressed by cells in response to myocardial stress.